U.S. markets close in 2 hours 37 minutes
  • S&P 500

    4,226.08
    +24.46 (+0.58%)
     
  • Dow 30

    34,707.16
    +158.63 (+0.46%)
     
  • Nasdaq

    13,739.87
    +107.03 (+0.79%)
     
  • Russell 2000

    2,270.21
    +28.79 (+1.28%)
     
  • Crude Oil

    64.92
    +0.21 (+0.32%)
     
  • Gold

    1,833.30
    +17.60 (+0.97%)
     
  • Silver

    27.50
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2158
    +0.0090 (+0.74%)
     
  • 10-Yr Bond

    1.5750
    +0.0140 (+0.90%)
     
  • GBP/USD

    1.3986
    +0.0094 (+0.67%)
     
  • USD/JPY

    108.7000
    -0.3850 (-0.35%)
     
  • BTC-USD

    58,241.96
    +1,227.04 (+2.15%)
     
  • CMC Crypto 200

    1,506.36
    +70.58 (+4.92%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Recap: Danaher Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Danaher (NYSE:DHR) rose 0.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 62.50% year over year to $2.08, which beat the estimate of $1.87.

Revenue of $6,760,000,000 rose by 38.87% year over year, which beat the estimate of $6,530,000,000.

Looking Ahead

Danaher hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Jan 28, 2021

View more earnings on DHR

Time: 08:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/758/39359

Price Action

52-week high: $248.32

Company's 52-week low was at $119.60

Price action over last quarter: down 4.50%

Company Profile

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which adds to its life sciences segment.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.